MXPA05010926A - Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales. - Google Patents
Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales.Info
- Publication number
- MXPA05010926A MXPA05010926A MXPA05010926A MXPA05010926A MXPA05010926A MX PA05010926 A MXPA05010926 A MX PA05010926A MX PA05010926 A MXPA05010926 A MX PA05010926A MX PA05010926 A MXPA05010926 A MX PA05010926A MX PA05010926 A MXPA05010926 A MX PA05010926A
- Authority
- MX
- Mexico
- Prior art keywords
- proteins
- colloidal particles
- polypeptides
- polypeptide
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmaceutica para administracion parenteral que comprende una cantidad terapeuticamente eficaz de una proteina o polipeptido y particulas coloidales. Las particulas comprenden aproximadamente 1-20 por ciento mol de un lipido amfipatico derivado con un polimero hidrofilico biocompatible. La proteina o polipeptido se selecciona del grupo que consiste de (a) proteinas o polipeptidos capaces de enlazar externamente las particulas coloidales; (b) proteinas o polipeptidos capaces de enlazar polimeros de las familias polialquileter, acido polilactivo y poliglicolico; y (c) proteinas o polipeptidos que incluyen una secuencia de consenso de S/T-X/I/V/-I/V/Q/S-S/T-X-X-X-E, en donde X puede ser cualquier aminoacido y S, T, L, I, V, E y Q tienen sus significados convencionales. La proteina o polipeptido no es factor VIII (FVIII) y no esta encapsulada en las particulas coloidales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46270103P | 2003-04-15 | 2003-04-15 | |
PCT/IL2004/000327 WO2004091723A1 (en) | 2003-04-15 | 2004-04-15 | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05010926A true MXPA05010926A (es) | 2005-11-25 |
Family
ID=33299976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05010926A MXPA05010926A (es) | 2003-04-15 | 2004-04-15 | Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070167359A1 (es) |
EP (1) | EP1633440B1 (es) |
JP (1) | JP2006523683A (es) |
CN (1) | CN1774281B (es) |
AT (1) | ATE395101T1 (es) |
AU (1) | AU2004229253B2 (es) |
BR (1) | BRPI0409424B8 (es) |
CA (1) | CA2522179C (es) |
DE (1) | DE602004013769D1 (es) |
DK (1) | DK1633440T3 (es) |
ES (1) | ES2307009T3 (es) |
MX (1) | MXPA05010926A (es) |
PL (1) | PL1633440T3 (es) |
PT (1) | PT1633440E (es) |
WO (1) | WO2004091723A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2554161A1 (en) * | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmaceutical composition comprising factor VII encapsulated in micelles |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
GB201518172D0 (en) * | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
JPH0482839A (ja) * | 1990-07-20 | 1992-03-16 | Green Cross Corp:The | 蛋白質類・脂質小体複合体 |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
AU1916295A (en) * | 1994-02-08 | 1995-08-29 | Amgen, Inc. | Oral delivery of chemically modified proteins |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
WO1998032466A1 (en) * | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
EP1079805B1 (en) * | 1998-04-27 | 2004-11-24 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
WO2001005873A1 (en) * | 1999-07-14 | 2001-01-25 | Alza Corporation | Neutral lipopolymer and liposomal compositions containing same |
IL150895A0 (en) * | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
WO2002086117A1 (en) * | 2001-04-20 | 2002-10-31 | The University Of Vermont | Compositions and methods to control bleeding |
AU2002353485B2 (en) * | 2001-12-04 | 2009-01-15 | Ben Gurion University Of The Negev Research And Development Authority | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
-
2004
- 2004-04-15 JP JP2006507607A patent/JP2006523683A/ja active Pending
- 2004-04-15 CN CN2004800100998A patent/CN1774281B/zh not_active Expired - Lifetime
- 2004-04-15 PT PT04727664T patent/PT1633440E/pt unknown
- 2004-04-15 EP EP04727664A patent/EP1633440B1/en not_active Expired - Lifetime
- 2004-04-15 BR BRPI0409424A patent/BRPI0409424B8/pt active IP Right Grant
- 2004-04-15 PL PL04727664T patent/PL1633440T3/pl unknown
- 2004-04-15 MX MXPA05010926A patent/MXPA05010926A/es active IP Right Grant
- 2004-04-15 CA CA2522179A patent/CA2522179C/en not_active Expired - Fee Related
- 2004-04-15 AT AT04727664T patent/ATE395101T1/de not_active IP Right Cessation
- 2004-04-15 DK DK04727664T patent/DK1633440T3/da active
- 2004-04-15 US US10/553,357 patent/US20070167359A1/en not_active Abandoned
- 2004-04-15 WO PCT/IL2004/000327 patent/WO2004091723A1/en active IP Right Grant
- 2004-04-15 DE DE602004013769T patent/DE602004013769D1/de not_active Expired - Lifetime
- 2004-04-15 ES ES04727664T patent/ES2307009T3/es not_active Expired - Lifetime
- 2004-04-15 AU AU2004229253A patent/AU2004229253B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CN1774281A (zh) | 2006-05-17 |
EP1633440B1 (en) | 2008-05-14 |
PL1633440T3 (pl) | 2008-12-31 |
BRPI0409424B8 (pt) | 2021-05-25 |
CA2522179C (en) | 2012-02-14 |
EP1633440A1 (en) | 2006-03-15 |
CN1774281B (zh) | 2010-10-13 |
AU2004229253B2 (en) | 2009-11-05 |
AU2004229253A1 (en) | 2004-10-28 |
US20070167359A1 (en) | 2007-07-19 |
CA2522179A1 (en) | 2004-10-28 |
ATE395101T1 (de) | 2008-05-15 |
DK1633440T3 (da) | 2008-09-08 |
WO2004091723A1 (en) | 2004-10-28 |
BRPI0409424B1 (pt) | 2018-05-02 |
DE602004013769D1 (de) | 2008-06-26 |
BRPI0409424A (pt) | 2006-04-25 |
ES2307009T3 (es) | 2008-11-16 |
JP2006523683A (ja) | 2006-10-19 |
PT1633440E (pt) | 2008-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2476698A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
MXPA00010241A (es) | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. | |
MY129566A (en) | A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance | |
CA2370289A1 (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
EP1845107A3 (en) | RGD-enriched gelatine-like proteins with enhanced cell binding | |
DE60204714D1 (de) | Pharmakologische nahrungszusammensetzung zur nahrungsergängzung und nährwertverbesserung | |
EP1310558A3 (en) | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same | |
EP2261247A3 (en) | KDR peptides and vaccines comprising the same | |
HK1100223A1 (en) | Compositions and methods of use for mgd-csf in disease treatment | |
AUPP051497A0 (en) | Antimicrobial peptides | |
EP1319023B8 (en) | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof | |
BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
PL1633440T3 (pl) | Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne | |
WO2001005810A3 (de) | CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6? | |
CA2071757A1 (en) | Implant compositions containing a biologically active protein, peptide or polypeptide | |
HK1046648A1 (en) | Vaccines containing hybrid polypeptides consistingof at least two different allergenic proteins | |
NZ591827A (en) | Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject | |
EP1578772A4 (en) | CYTOKINS AND CYTOKIN RECEPTORS WITH REDUCED IMMUNOGENICITY | |
EP1790655A3 (en) | Biologically active peptides | |
WO2003002598A3 (en) | Peptides for use as translocation factors | |
DE60329115D1 (de) | Tumorantigenprotein und dessen verwendung | |
ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
WO2002083734A3 (en) | Modified calcitonin | |
CA2163805A1 (en) | Novel activating factor of leukocytes | |
EP2385124A3 (en) | Peptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |